1-Methyl-4-phenylpyridinium stereotactic infusion completely and specifically ablated the nigrostriatal dopaminergic pathway in rhesus macaque

PLoS One. 2015 May 26;10(5):e0127953. doi: 10.1371/journal.pone.0127953. eCollection 2015.

Abstract

Introduction: Complete and specific ablation of a single dopaminergic (DA) pathway is a critical step to distinguish the roles of DA pathways in vivo. However, this kind of technique has not been reported in non-human primates. This study aimed to establish a lesioning method with a complete and specific ablation.

Method: A carefully designed infusion route based on a MRI stereotactic technique was developed to deliver the highly selective dopaminergic toxin 1-methyl-4-phenylpyridinium (MPP+) unilaterally into multiple sites of compact part of substantia nigra (SNc) and striatum in monkeys. The nigrostriatal DA pathway was selected because lesioning of this pathway may induce symptoms that are suitable for evaluation. The pathological, behavioral, neuropharmacological, and clinical laboratorial data were collected to evaluate the lesioning effects.

Result: Pathological examination revealed a complete ablation of tyrosine hydroxylase positive (TH+) neurons in the SNc, while preserving intact TH+ neurons in the ventral tegmental area (VTA) nearby. TH+ projections in the striatum were also unilaterally lost. The monkeys displayed stable (>28 weeks) rotations and symptoms which were expected with loss of DA neurons in the SNc, with rest tremor being an exception. No item implied the presence of a severe side effect caused by the operation or the intracerebral MPP+ infusion. The results suggested that rest tremor may not directly rely on the nigrostriatal pathway.

Conclusion: Taken together, in addition to providing a specific nigrostriatal DA lesioned model, this method, combined with brain stimulation or other techniques, can be applied as a powerful tool for the complete lesion of any desired DA pathway in order to study its specific functions in the brain.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 1-Methyl-4-phenylpyridinium / administration & dosage*
  • 1-Methyl-4-phenylpyridinium / pharmacology
  • 1-Methyl-4-phenylpyridinium / therapeutic use*
  • Animals
  • Behavior, Animal
  • Body Weight / drug effects
  • Cell Count
  • Corpus Striatum / pathology
  • Dopaminergic Neurons / drug effects
  • Dopaminergic Neurons / pathology*
  • Hematologic Tests
  • Macaca mulatta
  • Male
  • Neural Pathways / drug effects
  • Neural Pathways / pathology*
  • Parkinson Disease / blood
  • Parkinson Disease / drug therapy
  • Respiration / drug effects
  • Rotation
  • Stereotaxic Techniques*
  • Substantia Nigra / drug effects
  • Substantia Nigra / pathology*
  • Tyrosine 3-Monooxygenase / metabolism

Substances

  • Tyrosine 3-Monooxygenase
  • 1-Methyl-4-phenylpyridinium

Grants and funding

This work was supported by grants from the Strategic Priority Research Program of CAS (XDB02020000), National Program on Key Basic Research Project (973 Programs 2015CB755605, 2012CB825503, 2012CBA01304), Key Program of the Chinese Academy of Sciences (KZCC-EW-103-2), Training Program of the Major Research Plan of the National Natural Science Foundation of China (91332120), National Natural Science Foundation of China (31271167, 81271495, 81471312, 81271248), The Yunnan Provincial Project to Attract One-hundred Exceptional Talents from Overseas, Selected Frontier Scientific Significant Breakthrough Project of CAS, International Cooperation Projection (2011C14026) of Zhejiang Province Department of Science and Technology. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.